🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating globally, with figures suggesting over 82 million infections per year. Particularly high rates are reported in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The global health body has listed it as a "critical concern". A tracking program revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Secure Clearance

Zoliflodacin, alternatively called a brand name, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers believe that specific application of this new drug will help slow the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in the same week. This drug, which is additionally indicated for urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.

“This milestone marks a significant shift in the therapy of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Data and Worldwide Availability

Based on data detailed in a prominent scientific publication, the new drug cured over nine in ten of uncomplicated infections. This puts it on an comparable level with the existing first-line therapy, which combines two antibiotics. The research included nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to register and commercialise the drug in numerous regions with limited resources.

Clinicians on the front lines have expressed hope. Having a single-dose, oral treatment of this kind is seen as a "game-changer" for managing the epidemic. This is deemed crucial to alleviate the strain of the illness for people and to stop the proliferation of extremely resistant gonorrhoea around the world.